StockNews upgraded Abeona Therapeutics (NASDAQ:ABEO) from Sell to Hold, with target price updates and rating changes from other analysts.
StockNews upgraded Abeona Therapeutics (NASDAQ:ABEO) from Sell to Hold, while Stifel Nicolaus issued a Buy rating with a $21.00 target, Cantor Fitzgerald lowered its target from $28.00 to $21.00 and gave an Overweight rating, and HC Wainwright reiterated a Buy rating with a $15.00 target. Abeona Therapeutics, a clinical-stage biopharmaceutical co, focuses on gene therapy for rare diseases; institutional investors own 80.56% of its stock.
August 16, 2024
5 Articles